Editorial
Evidence vs. Claims
A candid audit of the gap between peer-reviewed peptide science and the claims circulated by popular social-media voices in the category. We do not name individuals; the patterns speak for themselves.
Peptide research is a legitimate and interesting field. It is also one of the most overclaim-prone corners of contemporary health content. The same molecule can, in the space of a single 20-minute YouTube video, be described as "healing tissues," "reversing aging," "fighting cancer," and "fixing your mitochondria" — without the evidence for any of those claims being addressed.
This page exists because Open Assay's whole value proposition depends on being honest when the evidence is thin. The sections below pair four common peptide narratives with the underlying primary literature, so you can see where the evidence genuinely is — and where the stories outrun it.
Case 1 — BPC-157: single-lab dominance
The claim: BPC-157 "does everything" — heals tendons, ligaments, the gut, the brain, suppresses cancer, and is "better than any drug."
The evidence base: more than 80% of PubMed records on BPC-157 list one research group (Sikiric/Seiwerth, University of Zagreb) as first or senior author. There is no completed, peer-reviewed Phase II or III human trial of BPC-157. The peptide was placed on FDA's 503A Category 2 list in 2020, meaning it was identified as having significant safety concerns as a compounding candidate.
Two notable exceptions to the single-lab pattern are worth citing. The 2011 and 2014 Chang papers (rat tendon fibroblasts) and the 2017 Hsieh paper on VEGFR2-mediated angiogenesis come from an independent Taiwanese research group. They establish plausible mechanisms in cell-based and rodent systems. But the Hsieh paper's finding — that BPC-157 activates VEGFR2 signaling and drives new vessel formation — also raises a theoretical tumor-promotion concern, because the same pathway is implicated in tumor angiogenesis. That caveat is almost never mentioned alongside the "BPC-157 fights cancer" claims in consumer-facing content.
See the full citations on our BPC-157 reference page.
Case 2 — MOTS-c: mouse healthspan is not human lifespan
The claim: MOTS-c "reverses aging" and extends healthy life.
The evidence base: real and improving, but human-therapeutic data does not exist yet. The 2015 Lee discovery paper in Cell Metabolism identified MOTS-c as a mitochondrial-derived peptide that activates AMPK. The 2021 Reynolds paper in Nature Communications— the single best human-adjacent study on MOTS-c — showed that acute exercise raised MOTS-c levels approximately 12-fold in human skeletal muscle, and that intermittent MOTS-c injections improved running capacity and healthspan in aged mice. There is no published human randomized trial of exogenous MOTS-c.
Healthspan gains in 22-month-old mice do not translate to lifespan extension in humans. Strong preclinical mechanism plus correlational human biomarker data is real science. Marketing it as "aging reversal" is not.
Full references on our MOTS-c reference page.
Case 3 — SS-31: the negative Phase 3 that doesn't get airtime
The claim: SS-31 (elamipretide) "fixes your mitochondria" and is a universal mitochondrial restorative.
The evidence base: mechanistically compelling. SS-31 binds cardiolipin in the inner mitochondrial membrane, and Szeto-lab mechanism work is real. But: MMPOWER-3 (Karaa et al., Neurology, 2023) — the Phase 3 placebo-controlled randomized trial in adults with primary mitochondrial myopathy, n=218, 24 weeks of subcutaneous elamipretide 40 mg daily — did not meet either primary endpoint. The 6-minute walk test and PMMSA fatigue score did not show statistically significant improvement versus placebo. This is Class I negative evidence in the target indication.
A subgroup with nuclear-DNA variants showed a signal, and development continues in other indications. But "SS-31 fixes your mitochondria" as a general framing omits the single most important piece of clinical evidence about SS-31.
Full references on our SS-31 reference page.
Case 4 — Epitalon: telomerase from a single in-vitro experiment
The claim: Epitalon activates telomerase, elongates telomeres, and extends lifespan.
The evidence base: one 2003 paper from the Khavinson group in Saint Petersburg that reported telomerase induction and ~10 extra population doublings in a single line of human fetal pulmonary fibroblasts. That is the load-bearing citation. Subsequent Russian longitudinal work from the same institute reported mortality and morbidity improvements in elderly cohorts taking Epithalamin, the bovine pineal preparation whose synthetic analog is Epitalon.
Neither the in-vitro telomerase finding nor the long-term Russian cohort data has been independently replicated by Western laboratories in rigorous randomized trials. Fetal-fibroblast in-vitro telomerase activity and aging-reversal in humans are not the same thing. Single-lab claims that have not been independently replicated — regardless of how compelling the mechanism sounds — belong in Tier 4 of our evidence scale.
Full references on our Epitalon reference page.
The underlying pattern
Across these four cases, the same failure modes recur:
- Confident therapeutic claims made on the basis of preclinical or in-vitro data with no supporting human trial.
- Silence about negative pivotal trials when they contradict the narrative.
- Single-lab findings treated as settled science without waiting for independent replication.
- Under-disclosed financial relationships between content creators and the suppliers of the peptides being discussed.
- Extrapolation from mouse healthspan or cell culture to human lifespan, cognition, or body composition without the intervening data.